Integer's CRM Division Head Eased Out Amid Active Sale Process
Integer's President of Cardiac Rhythm Management & Neuromodulation, Jim Stephens, has been moved to a newly created Executive Vice President of Special Projects role with a fixed end date of March 31, 2027 — and no successor named. The CRM & Neuromodulation segment generated $668.8 million in 2025 revenue, roughly 36% of Integer's total, making it the likely centerpiece of any strategic transaction. Stephens's exit agreement includes explicit change-of-control protections through that same March 2027 deadline, and layers on top of a $451,350 retention bonus awarded six weeks earlier that partially vests only upon a deal closing. Together, the structured departure window and deal-contingent pay stack signal that Integer's internal planning horizon for a potential transaction runs no later than early 2027.
